Stem Cells: Biologics for Regeneration

Nelson, Timothy J.; Behfar, Atta; Terzic, André

doi:10.1038/clpt.2008.146

Cited by 40 publications

(31 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Classified as "biologics," stem cells are a distinct class of medications produced by means of biological processes (22,23). In contrast to traditional pharmaceuticals, regenerative cytotherapy products contain viable cells as the active ingredient (24). Worldwide, over 3,000 patients with ischemic heart disease have received stem cell therapy in a clinical trial setting.…”

Section: See Pages 2232 and 2244mentioning

confidence: 99%

Regenerative Medicine

Terzic

Nelson

2010

Journal of the American College of Cardiology

View full text Add to dashboard Cite

Section: See Pages 2232 and 2244mentioning

confidence: 99%

Regenerative Medicine

Terzic

Nelson

2010

Journal of the American College of Cardiology

View full text Add to dashboard Cite

“…For example, organ or tissue transplantation (Haberal et al 1999;Broelsch et al 2003), embryonic and adult stem cells (Nishikawa et al 2008;Nelson et al 2008;Edalatmanesh et al 2010;Neshati et al 2010) or induced pluripotent stem (iPS) cells (Takahashi and Yamanaka 2006) are potential therapeutic means which can be used for clinical purposes, but have some drawbacks, including lack of available tissues for transplantation, ethical controversies in using fetal tissues and embryonic stem cells (Adams et al 1996), oncogenic concerns in using embryonic stem cells, iPS cells and adult stem cells Jiang et al 2008;Ghosh et al 2011;Soltanian and Matin 2011), practical difficulties in identifying and isolating adult stem cells, low efficiency in production of iPS cells ), inflammation induction of iPS-derived products (Zhao et al 2011), and also immune response (Yañez et al 2006). In view of these disadvantages, transdifferentiation appears as a promising alternative that addresses most of these issues.…”

Section: Clinical Significance Of Transdifferentiationmentioning

confidence: 99%

Transdifferentiation: a cell and molecular reprogramming process

Sisakhtnezhad

Matin

2012

Cell Tissue Res

View full text Add to dashboard Cite

Evidence has emerged recently indicating that differentiation is not entirely a one-way process, and that it is possible to convert one cell type to another, both in vitro and in vivo. This phenomenon is called transdifferentiation, and is generally defined as the stable switch of one cell type to another. Transdifferentiation plays critical roles during development and in regeneration pathways in nature. Although this phenomenon occurs rarely in nature, recent studies have been focused on transdifferentiation and the reprogramming ability of cells to produce specific cells with new phenotypes for use in cell therapy and regenerative medicine. Thus, understanding the principles and the mechanism of this process is important for producing desired cell types. Here some well-documented examples of transdifferentiation, and their significance in development and regeneration are reviewed. In addition, transdifferentiation pathways are considered and their potential molecular mechanisms, especially the role of master switch genes, are considered. Finally, the significance of transdifferentiation in regenerative medicine is discussed.

show abstract

“…Current approaches to restore normal function of affected tissues and organs rely on pharmacotherapy, transplantation and implantation of medical devices, which have limited applicability, fail to provide optimal clinical solutions and can result in life-threatening outcomes [1]. The burden of tissue and organ deficiencies therefore poses a critical need for the development of new therapeutic solutions that can effectively and safely restore normal tissue structure and function.…”

mentioning

confidence: 99%

Make no bones about it: cells could soon be reprogrammed to grow replacement bones?

Peppo

Marolt

2013

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Recent developments in nuclear reprogramming allow the generation of patient-matched stem cells with broad potential for applications in cell therapies, disease modeling and drug discovery. An increasing body of work is reporting the derivation of lineage-specific progenitors from human-induced pluripotent stem cells (hiPSCs), which could in the near future be used to engineer personalized tissue substitutes, including those for reconstructive therapies of bone. Although the potential clinical impact of such technology is not arguable, significant challenges remain to be addressed before hiPSC-derived progenitors can be employed to engineer bone substitutes of clinical relevance. The most important challenge is indeed the construction of personalized multicellular bone substitutes for the treatment of complex skeletal defects that integrate fast, are immune tolerated and display biofunctionality and long-term safety. As recent studies suggest, the merging of iPSC technology with advanced biomaterials and bioreactor technologies offers a way to generate bone substitutes in a controllable, automated manner with potential to meet the needs for scale-up and requirements for translation into clinical practice. It is only via the use of state-of-the-art cell culture technologies, process automation under GMP-compliant conditions, application of appropriate engineering strategies and compliance with regulatory policies that personalized lab-made bone grafts can start being used to treat human patients.

show abstract

Stem Cells: Biologics for Regeneration

Cited by 40 publications

References 29 publications

Regenerative Medicine

Regenerative Medicine

Transdifferentiation: a cell and molecular reprogramming process

Make no bones about it: cells could soon be reprogrammed to grow replacement bones?

Contact Info

Product

Resources

About